Stephen Plantholt, MD
Cardiovascular Disease · Baltimore, MDNPI 1265426274
Payments from drug & device makers
Across 1,335 payments — averaging $423.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$251K
- Alnylam Pharmaceuticals Inc.$204K
- Eli Lilly$98K
- Novartis$5K
- Boehringer Ingelheim$795
- Amgen$545
- plus $5K from 33 others
Across 2 payments — averaging $82.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$166
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $251,403 |
| Alnylam Pharmaceuticals Inc. | 844 | $204,207 |
| Eli Lilly | 9 | $98,147 |
| Novartis | 71 | $4,798 |
| Boehringer Ingelheim | 37 | $795 |
| Amgen | 23 | $545 |
| E.r. Squibb & Sons, L.L.C. | 22 | $522 |
| Esperion Therapeutics, Inc. | 25 | $426 |
| Scpharmaceuticals Inc. | 14 | $410 |
| Bayer | 14 | $399 |
| Pfizer | 27 | $341 |
| Johnson & Johnson | 26 | $334 |
| Merck | 16 | $295 |
| AstraZeneca | 15 | $283 |
| Medtronic | 3 | $276 |
| Boston Scientific | 3 | $190 |
| Baxter Healthcare | 5 | $175 |
| Novo Nordisk | 8 | $160 |
| Atricure, Inc. | 3 | $112 |
| Abbott | 2 | $111 |
| Amarin Pharma, Inc. | 7 | $110 |
| Lexicon Pharmaceuticals, Inc. | 5 | $106 |
| Daiichi Sankyo Inc. | 3 | $78 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 4 | $66 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $57 |
| Lilly USA, LLC | 3 | $51 |
| Gilead | 4 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Philips North America LLC | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| GSK | 1 | $14 |
How this compares
$564,804 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Baltimore
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
- Jesse DoranBaltimore$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.